Abstract
The aim of this study is to evaluate the feasibility and usefulness of the human umbilical cord mesenchymal stem cells (hUC-MSCs) and hyaluronan acid (HA) combination to attenuate osteoarthritis progression in the knee while simultaneously providing some insights on the mitigation mechanism. In vitro, the effect of hUC-MSCs with HA treatment on chondrocyte cell viability and the cytokine profile were analyzed. Additionally, the antioxidation capability of hUC-MSCs-CM (conditioned medium) with HA towards H2O2-induced chondrocyte cell damage was evaluated. The HA addition increased the hUC-MSC antioxidation capability and cytokine secretion, such as Dickkopf-related protein 1 (DKK-1) and hepatocyte growth factor (HGF), while no adverse effect on the cell viability was observed. In vivo, the intra-articular injection of hUC-MSCs with HA to a mono-iodoacetate (MIA)-induced knee osteoarthritis (KOA) rat model was performed and investigated. Attenuation of the KOA progression in the MIA-damaged rat model was seen best in hUC-MSCs with a HA combination compared to the vehicle control or each individual element. Combining hUC-MSCs and HA resulted in a synergistic effect, such as increasing the cell therapeutic capability while incurring no observable adverse effects. Therefore, this combinatorial therapy is feasible and has promising potential to ameliorate KOA progression.
Highlights
Osteoarthritis (OA) is a debilitating progressive disease affecting the joints that could be divided into two types: primary and secondary
Through the MIA-induced OA animal model conducted in this study, we observed that a combination of hUC-Mesenchymal stem cells (MSCs) and hyaluronan acid (HA) could synergistically mitigate the cartilage degradation process better when compared to each individual administration
Where hUC-MSCs exposed to 0.1% HA increased the secretion of Dickkopf-related protein 1 (DKK-1), hepatocyte growth factor (HGF) and a higher antioxidation capability by might provide an insight on the mechanism of this event
Summary
Osteoarthritis (OA) is a debilitating progressive disease affecting the joints that could be divided into two types: primary and secondary. Both types involved the degeneration of cartilage in joints; primary OA is mostly caused by wear and tear on joints that becomes increasingly apparent as people age, while specific triggers resulting in cartilage breakdown cause secondary OA to manifest, such as genetics [1], obesity [2], inflammation [3], etc. The administration of HA to KOA patients is recommended when other pharmacologic treatments, such as glucocorticoid injections, fail to show results [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
